|
AARS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.6583957257742E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.93090013264919E-10 |
| Normal-vs-Stage2 |
3.16940000000265E-06 |
| Normal-vs-Stage3 |
3.49420048451066E-10 |
| Normal-vs-Stage4 |
2.79660000046533E-07 |
| Stage1-vs-Stage2 |
9.682600E-01 |
| Stage1-vs-Stage3 |
2.167800E-01 |
| Stage1-vs-Stage4 |
7.745800E-01 |
| Stage2-vs-Stage3 |
4.045600E-01 |
| Stage2-vs-Stage4 |
8.084600E-01 |
| Stage3-vs-Stage4 |
5.601200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06959996415412E-10 |
| Normal-vs-AfricanAmerican |
4.101600E-03 |
| Normal-vs-Asian |
1.137490E-03 |
| Caucasian-vs-AfricanAmerican |
1.724210E-01 |
| Caucasian-vs-Asian |
2.151500E-02 |
| AfricanAmerican-vs-Asian |
7.628400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.92469999832556E-08 |
| Normal-vs-Female |
5.21305221212742E-12 |
| Male-vs-Female |
3.587200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63159996624529E-09 |
| Normal-vs-Age(41-60Yrs) |
2.87539991816743E-10 |
| Normal-vs-Age(61-80Yrs) |
2.31250000259919E-08 |
| Normal-vs-Age(81-100Yrs) |
3.824800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.866200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.527200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.895200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.219400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.207800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.663000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.097300E-03 |
| Classical-VS-Follicular |
3.199600E-04 |
| Classical-VS-Other |
6.256000E-01 |
| Classical-VS-Normal |
2.00299999919551E-08 |
| Tall-VS-Follicular |
4.102200E-01 |
| Tall-VS-Other |
7.155000E-01 |
| Tall-VS-Normal |
1.45529999162619E-09 |
| Follicular-VS-Other |
4.610000E-01 |
| Follicular-VS-Normal |
5.46489520303339E-11 |
| Other-VS-Normal |
1.214070E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.11159986665643E-10 |
| Normal-vs-N1 |
2.98330000036984E-07 |
| N0-vs-N1 |
9.526800E-01 |
|
|
